Author

Sandra Garces

Institution: Bristol-Myers Squibb (United States)

Observed institutions: Amgen (United States), Bristol-Myers Squibb (United States)

ORCID: 0000-0002-6601-5155

Observed ORCID: 0000-0002-6601-5155

OpenAlex ID: A5103029236

Improving resource utilisation in SLE drug development through innovative trial design

2023 · Sandra Garces, Elaine Karis, et al. · Lupus Science & Medicine · 17

Therapeutic Drug Monitoring of Biologics: Current Practice, Challenges and Opportunities – a Workshop Report

2025 · Sophie Shubow, Michele Gunsior, et al. · The AAPS Journal · 11

Domains for inclusion in a novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): results of a modified Delphi study

2025 · Kathryn Connelly, Rachel Koelmeyer, et al. · Lupus Science & Medicine · 8

P132 Design of an adaptive, phase 2, placebo-controlled, dose-ranging study to assess the efficacy and safety of AMG 570 in subjects with active SLE and inadequate response to standard of care therapy

2020 · Lei Zhou, Hui Wang, et al. · Poster presentations · 3

PO:11:273 CD19 NEX-T® (BMS-986353), a chimeric antigen receptor (CAR) T cell therapy, for active SLE with inadequate response to glucocorticoids and at least 2 immunosuppressants: a phase 2 trial in progress

2026 · Brad Rovin, Joan T Merrill, et al.

PO:05:136 Measurement of kidney disease in a novel treatment response measure for systemic lupus erythematosus clinical trials

2026 · Kathryn Connelly, Eric F Morand, et al.

PO:05:137 Measurement of arthritis in a novel treatment response measure for systemic lupus erythematosus clinical trials

2026 · Kathryn Connelly, Eric F Morand, et al.

LO-033 Towards a novel clinical outcome assessment for systemic lupus erythematosus trials – first outcomes of an international consensus process

2023 · Kathryn Connelly, Laura Eades, et al.

Works count: 8

Citation count: 39

H-index: 3

I10-index: 2